Enovis (NYSE:ENOV) Insider Oliver Engert Buys 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 1,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were acquired at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enovis Price Performance

NYSE:ENOV opened at $25.39 on Wednesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The company has a 50-day moving average of $24.23 and a 200-day moving average of $28.12. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $40.69. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -1.23 and a beta of 1.46.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. The firm had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ENOV. UBS Group reissued a “buy” rating and set a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Canaccord Genuity Group cut their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. BTIG Research raised their price target on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Finally, Needham & Company LLC increased their price objective on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.43.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP acquired a new stake in shares of Enovis during the 3rd quarter worth approximately $83,435,000. Tributary Capital Management LLC raised its position in shares of Enovis by 91.5% during the 3rd quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock valued at $35,027,000 after acquiring an additional 551,613 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the period. Boston Partners boosted its position in shares of Enovis by 42.4% in the 2nd quarter. Boston Partners now owns 1,382,724 shares of the company’s stock worth $43,352,000 after purchasing an additional 411,744 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Enovis by 43.8% during the second quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock worth $42,105,000 after purchasing an additional 408,608 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.